Mizagliflozin (sebacate)  (Synonyms: DSP-3235 (sebacate); KGA-3235 (sebacate); GSK-1614235 (sebacate))

Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving vascular cognitive impairment caused by small vessel disease. Mizagliflozin sebacate improves blood flow and reverses vascular cognitive impairment by inhibiting neuronal SGLT1 activity. Mizagliflozin sebacate also showed the ability to increase the survival rate of IL-1β-treated PC12HS cells. Mizagliflozin sebacate promotes improvements in spatial learning and memory caused by small vessel disease in mouse models^[1].

1331.59

C₂₈H₄₄N₄O₈.1/2C₁₀H₁₈O₄

1169392-27-1

OC[C@H]([C@H]([C@@H]([C@H]1O)O)O)O[C@H]1OC2=NNC(C(C)C)=C2CC3=C(C=C(C=C3)OCCCNCC(C)(C)C(N)=O)C.OC(CCCCCCCCC(O)=O)=O.[0.5]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Inoue T, et al. Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation. Eur J Pharmacol. 2017 Jul 5;806:25-31.  [Content Brief]

  [2]. Mizagliflozin, a selective SGLT1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease  [Content Brief]

  [3]. Ohno H, et al. Absorption, disposition, metabolism and excretion of [14C]mizagliflozin, a novel selective SGLT1 inhibitor, in rats. Xenobiotica. 2019 Apr;49(4):463-473.  [Content Brief]